PRL and prostate cancer: Potential biomarkers to assess may include circulating soluble tumour necrosis factor receptor‐2 (Epstein et al., 2018), C‐reactive protein, insulin‐like growth factor‐1 and lactate dehydrogenase (for cancer in general) (Desai & Guddati, 2023; Feng et al., 2018; Zhang et al., 2024), testosterone and prolactin (in women, for breast cancer) (Aranha et al., 2022; Zhang et al., 2024), and prostate‐specific antigen and novel associated markers (Garrido et al., 2022) as well as coagulation markers (Lei et al., 2023) (in men, for prostate cancer).